INmune Bio (INMB) Reports Data on Combination Therapy with INB03 on Overcoming Resistance to HER2 Targeted Therapies in Breast Cancer - StreetInsider.com

6/16/2022 12:00:00 AM3 years 8 months ago

...

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premiumhere. INmune Bio, Inc. (NASDAQ: INMB) (the âCompanyâ), a clinical-stage immuno… [+2905 chars]

full article...